Contagion Editorial Team

New real-world evidence presented by GSK shows its RSV vaccine, Arexvy, was associated with substantial reductions in RSV-related hospitalizations and serious cardiovascular and respiratory complications among older adults.

After initially refusing to review Moderna’s investigational mRNA-based seasonal influenza vaccine, the company communicated with the FDA on a revised proposal to seek approval and the federal agency will now review the product. The vaccine's PDUFA decision date is August 5, 2026.

A newly proposed federal insurance rule for 2027 omits long-promised protections on co-pay assistance, allowing insurers and pharmacy benefit managers to continue diverting billions of dollars intended to help patients afford prescription drugs.

Findings from a real-world population study from Spain show that universal infant immunization with Beyfortus significantly reduced RSV-related hospitalizations not only in the first RSV season but also into the second year of life.

A 6-year study in Liberia shows that Lassa fever is frequently missed in febrile patients, leading to preventable deaths and underscoring the urgent need for earlier diagnosis and improved testing.

This week, listen in on commentary around the potential removal of the COVID-19 vaccine from the US market, read about FDA's refusal to review Moderna's influenza vaccine, CDC's investigation on invasive E coli, and more.

The FDA declined to review Moderna’s mRNA flu vaccine application for its mRNA-1010 product, and based its decision on it choice of comparator in a phase 3 trial, despite the absence of safety or efficacy concerns and prior FDA agreement on the study design. Moderna requested a meeting to understand the path forward with the vaccine.

A large international study published in The Lancet shows that obesity substantially increases the risk of severe illness and death from most infectious diseases, potentially accounting for more than 10% of infection-related deaths worldwide.

In a new policy paper, the American College of Physicians (ACP) argues that referring to physicians as “providers” is not merely semantic but contributes to the commercialization of medicine, eroding professional identity, ethical practice, and the physician–patient relationship.

This week, listen in on commentary around the ongoing measles outbreak, read our new Antibiotics Deconstructed column on IV fosfomycin, review data on metformin preventing long COVID, insights on diagnostic stewardship, and more.

In a phase 3 trial, the novel oral antiviral pritelivir demonstrated superior lesion healing and better tolerability than existing therapies in immunocompromised patients with refractory or resistant herpes simplex virus infections.

Findings from a growing body of randomized trials and real-world analyses show that starting metformin during acute SARS-CoV-2 infection is safe and significantly reduces the risk of developing long COVID.

A global review finds growing antimicrobial resistance among the main bacteria causing meningitis—especially in low- and middle-income countries—raising concerns about the continued effectiveness of standard treatments and the urgent need for stronger surveillance.

MicuRx Pharmaceuticals has received FDA clearance to begin a phase 2a clinical trial of MRX-5, a novel oral antibacterial therapy for patients with Mycobacterium abscessus pulmonary disease.

This week, read about the latest number of confirmed cases of measles in the US, novel findings around UTI treatment failure, an overview of zoliflodacin and gepotidacin, and more.

The American Academy of Pediatrics (AAP) has published its 2026 immunization schedule, reaffirming routine vaccination to protect children and adolescents against 18 preventable diseases.

Fedora Pharmaceuticals is presenting new preclinical data at the IMARI conference demonstrating that its lead candidate, FPI-2119, shows strong activity against some of the most dangerous drug-resistant Gram-negative infections, supporting its advancement toward clinical trials.

In the final FY2026 spending bill, Congress rejected proposed House Republican cuts of more than $1.7 billion and instead maintained bipartisan funding for HIV prevention and treatment programs, while urging the Trump administration to focus on effective implementation.

The federal agency gave the nod for Acon Laboratories’ Flowflex Plus RSV + Flu A/B + COVID 4-in-1 test that can detect all those respiratory viruses in a single test, which is indicated for use in both adults and children as young as 6 months.

Scynexis has secured FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for its next-generation antifungal SCY-247, underscoring the drug’s potential to address the escalating global threat of multidrug-resistant fungal infections such as Candida auris.

This week, read about the CDC's analysis on the continuing burden of COVID-19 on a certain population, watch an Emory nurse provide an overview of donning and doffing personal protective equipment when caring for patients with high-consequence infectious disease, a review of diagnostics and treatments for invasive candidiasis, and more.

In a joint statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F Kennedy, they announced the termination of the country’s membership in the global health organization.

Zepto Life Technology has introduced its FungiFlex Mold Panel, a plasma-based molecular test offered through a CLIA-certified reference laboratory that delivers rapid, noninvasive detection of 14 clinically important mold species linked to invasive fungal infections.

Valneva has voluntarily withdrawn its US regulatory applications for its chikungunya vaccine, IXCHIQ, after the FDA suspended the license and placed the program on clinical hold pending investigation of a newly reported serious adverse event.

The partnership is a global collaboration to develop Debio1453, a first-in-class antibiotic targeting multidrug-resistant gonorrhea, aiming to strengthen the fragile antibiotic pipeline and ensure future treatment options.

Nicholas Van Hise, PharmD, discusses a real world study, ROAR, showing that fecal microbiota, live-jslm (RBL), maintains strong efficacy and safety in preventing recurrent Clostridioides difficile infection (rCDI) in routine US clinical practice.

This week, read articles from our recent issue on topics including invasive fungal disease in transplantation, lenacapavir's role in PrEP, antimicrobial treatment around non–carbapenemase-producing carbapenem-resistant enterobacterales, and more.

We are launching our new monthly column looking at federal regulatory topics including recent decisions. In this column, we look at the FDA approvals of 2 antibiotics last month.

Here are some therapeutics and a vaccine that will be reporting data, starting a trial, or filing their data to regulatory agencies in order to seek approval this year.

This week, listen in on commentary around the changes to the childhood vaccine schedule, read SIDP's column on the next-generation antifungals as well as combination therapeutics for Candida auris, and the Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing breakpoint recommendations.